Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that it has been allowed a key patent for its oral insulin drug.
The United States Patent and Trademark Office has allowed a U.S. patent for the technology, “Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same.”
“This is an important patent in Oramed’s patent portfolio that protects a key aspect of our breakthrough technology,” said Nadav Kidron, CEO of Oramed in a statement. “The protease inhibitors allow the insulin and other proteins to travel through the body intact.”
Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801).
The company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration.
In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901). GLP-1 is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Exenatide, a GLP-1 analog, is currently marketed in injectable form only and is indicated for the treatment of Type 2 diabetes.
Exenatide induces insulin release at increased glucose levels and causes a feeling of satiety, which results in reduced food intake and weight loss.
Oramed’s oral GLP-1 capsule based on the company’s PODTM technology could significantly increase compliance and become a valuable tool in the treatment of diabetes.
- Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology. (2019, March 28). PR Newswire. Retrieved: https://prnmedia.prnewswire.com/news-releases/oramed-patent-allowed-in-the-us-for-key-aspect-of-its-oral-delivery-technology-300820162.html